Pemilihan kerjaya di kalangan pelajar aliran perdagangan sekolah menengah teknik : satu kajian kes

This research is a survey to determine the career chosen of form four student in commerce streams. The important aspect of the career chosen has been divided into three, first is information about career, type of career and factor that most influence students in choosing a career. The study was conducted at Sekolah Menengah Teknik Kajang, Selangor Darul Ehsan. Thirty six form four students was chosen by using non-random sampling purpose method as respondent. All information was gather by using questionnaire. Data collected has been analyzed in form of frequency, percentage and mean. Results are performed in table and graph. The finding show that information about career have been improved in students career chosen and mass media is the main factor influencing students in choosing their career

Fuzzy rule-based system applied to risk estimation of cardiovascular patients

Cardiovascular decision support is one area of increasing research interest. On-going collaborations between clinicians and computer scientists are looking at the application of knowledge discovery in databases to the area of patient diagnosis, based on clinical records. A fuzzy rule-based system for risk estimation of cardiovascular patients is proposed. It uses a group of fuzzy rules as a knowledge representation about data pertaining to cardiovascular patients. Several algorithms for the discovery of an easily readable and understandable group of fuzzy rules are formalized and analysed. The accuracy of risk estimation and the interpretability of fuzzy rules are discussed. Our study shows, in comparison to other algorithms used in knowledge discovery, that classifcation with a group of fuzzy rules is a useful technique for risk estimation of cardiovascular patients. © 2013 Old City Publishing, Inc

Modeling Stroke Diagnosis with the Use of Intelligent Techniques

The purpose of this work is to test the efficiency of specific intelligent classification algorithms when dealing with the domain of stroke medical diagnosis. The dataset consists of patient records of the ”Acute Stroke Unit”, Alexandra Hospital, Athens, Greece, describing patients suffering one of 5 different stroke types diagnosed by 127 diagnostic attributes / symptoms collected during the first hours of the emergency stroke situation as well as during the hospitalization and recovery phase of the patients. Prior to the application of the intelligent classifier the dimensionality of the dataset is further reduced using a variety of classic and state of the art dimensionality reductions techniques so as to capture the intrinsic dimensionality of the data. The results obtained indicate that the proposed methodology achieves prediction accuracy levels that are comparable to those obtained by intelligent classifiers trained on the original feature space

Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.

BackgroundEarly detection of adverse effects of novel therapies and understanding of their mechanisms could improve the safety and efficiency of drug development. We have retrospectively applied large-scale proteomics to blood samples from ILLUMINATE (Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events), a trial of torcetrapib (a cholesterol ester transfer protein inhibitor), that involved 15 067 participants at high cardiovascular risk. ILLUMINATE was terminated at a median of 550 days because of significant absolute increases of 1.2% in cardiovascular events and 0.4% in mortality with torcetrapib. The aims of our analysis were to determine whether a proteomic analysis might reveal biological mechanisms responsible for these harmful effects and whether harmful effects of torcetrapib could have been detected early in the ILLUMINATE trial with proteomics.MethodsA nested case-control analysis of paired plasma samples at baseline and at 3 months was performed in 249 participants assigned to torcetrapib plus atorvastatin and 223 participants assigned to atorvastatin only. Within each treatment arm, cases with events were matched to controls 1:1. Main outcomes were a survey of 1129 proteins for discovery of biological pathways altered by torcetrapib and a 9-protein risk score validated to predict myocardial infarction, stroke, heart failure, or death.ResultsPlasma concentrations of 200 proteins changed significantly with torcetrapib. Their pathway analysis revealed unexpected and widespread changes in immune and inflammatory functions, as well as changes in endocrine systems, including in aldosterone function and glycemic control. At baseline, 9-protein risk scores were similar in the 2 treatment arms and higher in participants with subsequent events. At 3 months, the absolute 9-protein derived risk increased in the torcetrapib plus atorvastatin arm compared with the atorvastatin-only arm by 1.08% (P=0.0004). Thirty-seven proteins changed in the direction of increased risk of 49 proteins previously associated with cardiovascular and mortality risk.ConclusionsHeretofore unknown effects of torcetrapib were revealed in immune and inflammatory functions. A protein-based risk score predicted harm from torcetrapib within just 3 months. A protein-based risk assessment embedded within a large proteomic survey may prove to be useful in the evaluation of therapies to prevent harm to patients.Clinical trial registrationURL: https://www.clinicaltrials.gov. Unique identifier: NCT00134264

Proteomics in cardiovascular disease: recent progress and clinical implication and implementation

Introduction: Although multiple efforts have been initiated to shed light into the molecular mechanisms underlying cardiovascular disease, it still remains one of the major causes of death worldwide. Proteomic approaches are unequivocally powerful tools that may provide deeper understanding into the molecular mechanisms associated with cardiovascular disease and improve its management. Areas covered: Cardiovascular proteomics is an emerging field and significant progress has been made during the past few years with the aim of defining novel candidate biomarkers and obtaining insight into molecular pathophysiology. To summarize the recent progress in the field, a literature search was conducted in PubMed and Web of Science. As a result, 704 studies from PubMed and 320 studies from Web of Science were retrieved. Findings from original research articles using proteomics technologies for the discovery of biomarkers for cardiovascular disease in human are summarized in this review. Expert commentary: Proteins associated with cardiovascular disease represent pathways in inflammation, wound healing and coagulation, proteolysis and extracellular matrix organization, handling of cholesterol and LDL. Future research in the field should target to increase proteome coverage as well as integrate proteomics with other omics data to facilitate both drug development as well as clinical implementation of findings

Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program

Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's Disease Biomarker Program (PDBP) and other mechanisms, no single PD marker or set of markers are ready for clinical use. Here we discuss the current state of biomarker discovery for platforms relevant to PDBP. We discuss the role of the PDBP in PD biomarker identification and present guidelines to facilitate their development. These guidelines include: harmonizing procedures for biofluid acquisition and clinical assessments, replication of the most promising biomarkers, support and encouragement of publications that report negative findings, longitudinal follow-up of current cohorts including the PDBP, testing of wearable technologies to capture readouts between study visits and development of recently diagnosed (de novo) cohorts to foster identification of the earliest markers of disease onset